Head & Neck Cancers | Specialty

Dr. Rodriguez on Systemic Therapy in Salivary Gland Cancer

August 4th 2016

Cristina P. Rodriguez, MD, hematology oncologist, University of Washington School of Medicine in Seattle, discusses the emerging role of systemic therapy for patients with salivary gland cancer.

Late-Stage Afatinib Trials Halted in Head and Neck Cancer

July 26th 2016

Two phase III trials examining afatinib (Gilotrif) in head and neck cancer have been stopped after an independent panel determined the pan-HER inhibitor was unlikely to demonstrate an efficacy benefit over placebo.

Vemurafenib Effective for BRAF-Mutant Thyroid Cancer

July 26th 2016

Treatment with vemurafenib (Zelboraf) demonstrated an objective response rate of up to 38.5% for patients with radioactive iodine-refractory BRAF V600E-mutant papillary thyroid cancer who were multikinase inhibitor-naive.

Personalized Strategies Vital in Thyroid Cancer Care

July 23rd 2016

After a decade of advances in the treatment of differentiated thyroid cancer, researchers are looking for ways to improve outcomes through a more personalized approach that includes risk-based strategies and appropriate use of molecular testing.

FDA Grants Nivolumab Priority Review for Head and Neck Cancer

July 18th 2016

The FDA has granted a priority review designation to nivolumab as a treatment for patients with previously treated metastatic or recurrent squamous cell carcinoma of the head and neck.

Lenvatinib PFS Benefit Sustained in Thyroid Cancer

July 15th 2016

The progression-free survival benefit with lenvatinib over placebo in patients with radioactive iodine–refractory differentiated thyroid cancer was sustained in an updated analysis of the phase III SELECT trial.

Dr. Haraf on Induction Chemotherapy With Radiation For Advanced Head and Neck Cancer

July 14th 2016

Individualizing Care for Elderly Patients With Localized Head and Neck Cancer

July 13th 2016

Although paradigms for treating older patients with head and neck cancer are not well defined, advancements in targeted and immunotherapies and less toxic radiation regimens suggest that physicians can aim for a more individualized approach to treating this patient population.

Expert Provides Insight on Biomarker Research in Thyroid Cancer

July 13th 2016

Marcia S. Brose, MD, PhD, sheds light on the biomarker assessment of the DECISION trial and the overall developments with biomarker research in the field of differentiated thyroid cancer.

Pembrolizumab Shows Potential in Advanced Thyroid Cancer

July 12th 2016

Pembrolizumab (Keytruda) demonstrated promising antitumor activity with durable responses in patients with advanced thyroid cancer.

Brose Discusses Lenvatinib's Lasting Impact in Treatment of Thyroid Cancer

July 11th 2016

Marcia S. Brose, MD, PhD, discusses the updated SELECT findings, how practitioners are treating patients with lenvatinib, how its use compares with sorafenib, and the challenges that still exist with both therapies for patients with thyroid cancer.

Potential Biomarkers Identified for Pembrolizumab in Head and Neck Cancer

July 8th 2016

PD-L2 and the IFN-γ 6-gene signature may offer options beyond PD-L1 to predict response to pembrolizumab (Keytruda) in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Buparlisib Extends PFS in Head and Neck Cancer

July 7th 2016

Adding the pan-PI3K inhibitor buparlisib (BKM120) to chemotherapy reduced the risk of disease progression or death by 35% in patients with advanced head and neck squamous cell carcinoma.

Dr. Churilla on Impact of Health Insurance Status on Patients With HNSCC

July 5th 2016

Thomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.

KEYNOTE-012 Investigator Explains Promise of Pembrolizumab in HNSCC

June 29th 2016

Ranee Mehra, MD, discusses what the KEYNOTE-012 findings could mean for patients, the growing role for the immunotherapy agent in head and neck cancer, and what else is on the horizon for the treatment landscape.

The Impact of Lymphedema in Patients With Head and Neck Cancer

June 28th 2016

Jan S. Lewin, PhD, professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the impact of lymphedema in patients with head and neck cancer.

Researchers Investigate Increased Incidence of Thyroid Cancer in California

June 28th 2016

To investigate the possibility of environmental impacts as a predisposition for thyroid cancer, researchers sought to identify counties in California with possible geographic clustering of advanced thyroid cancer cases.

Dr. Mehra on KEYNOTE-012 Results of Pembrolizumab in Head and Neck Cancer

June 22nd 2016

Ranee Mehra, MD, chief, Head and Neck Hematology/Oncology, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the KEYNOTE-012 study, which examined the efficacy of pembrolizumab (Keytruda) in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Pembrolizumab Shows Robust Activity in Head and Neck Cancer

June 10th 2016

Pembrolizumab demonstrated an objective response rate of 18% in data from two clinical trials exploring the PD-1 inhibitor as a treatment for patients with pretreated recurrent or metastatic head and neck squamous cell carcinoma.

Dr. Ferris on Significance of CheckMate-141 Trial for Head and Neck Cancer

June 7th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).